Pasithea Therapeutics (KTTA) News Today → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Free KTTA Stock Alerts $7.24 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlinePasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancersglobenewswire.com - April 24 at 7:59 AMPasithea Therapeutics (NASDAQ:KTTA) Shares Down 0.4% americanbankingnews.com - April 19 at 2:38 AMmarketbeat.com - February 15 at 2:38 PMPasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004finance.yahoo.com - February 13 at 10:03 AMPasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Positionfinance.yahoo.com - January 8 at 9:23 AMPasithea Jumps as FDA Grants IND Status to Cancer Treatmentmsn.com - January 2 at 1:13 PMPasithea Therapeutics' IND Application For PAS-004 Gets FDA Acceptancemarkets.businessinsider.com - January 2 at 1:13 PMPasithea conducts 1-for-20 reverse stock split, gets FDA okay for studyseekingalpha.com - January 2 at 1:13 PMPasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patientsfinance.yahoo.com - January 2 at 1:13 PMPasithea Therapeutics Stock (NASDAQ:KTTA) Dividends: History, Yield and Datesbenzinga.com - January 1 at 7:40 PMmarketbeat.com - January 1 at 6:11 AMPasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023finance.yahoo.com - December 28 at 6:44 PMPasithea Therapeutics Announces Results from 2023 Annual Meetingfinance.yahoo.com - December 19 at 8:24 PMWhy Is Pasithea Therapeutics (KTTA) Stock Down 12% Today?msn.com - December 13 at 9:32 AMNeurology Focused Pasithea Therapeutics Stock Soars Over 150% Today - Here's Whymsn.com - December 11 at 1:40 PMPasithea Announces Positive In Vivo Preclinical Data For PAS-004markets.businessinsider.com - December 11 at 1:40 PMPasithea stock soars as high as 190% on preclinical datamsn.com - December 11 at 1:40 PMWhy Is Pasithea Therapeutics (KTTA) Stock Up 105% Today?investorplace.com - December 11 at 12:02 PMPasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Modelsfinance.yahoo.com - December 11 at 8:39 AMPasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholdersfinance.yahoo.com - November 29 at 7:55 PMPasithea stock jumps 12% on update for anti-tumor drug PAS-004msn.com - November 29 at 2:55 PMPasithea Announces Receipt Of FDA Response Of Pre-IND Meeting For PAS-004 Clinical Developmentmarkets.businessinsider.com - November 29 at 9:55 AMPasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Developmentfinance.yahoo.com - November 29 at 9:55 AMPasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALSfinance.yahoo.com - November 9 at 9:52 AMPasithea Therapeutics Corp. Announces Final Results of Tender Offerfinance.yahoo.com - September 14 at 9:30 AMPasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conferencefinance.yahoo.com - September 7 at 7:42 PMPasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved survival and motor functionfinance.yahoo.com - August 1 at 5:37 PMWhat's Happening With Pasithea Therapeutics Stock Today?benzinga.com - July 20 at 1:55 PMPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cashfinance.yahoo.com - July 20 at 1:55 PMPasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.finance.yahoo.com - July 20 at 8:55 AMPasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cashfinance.yahoo.com - July 20 at 8:54 AMPasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directorsfinance.yahoo.com - June 30 at 9:51 AMPasithea Therapeutics Announces Completion of GMP Manufacturing for PAS-004finance.yahoo.com - June 29 at 1:22 PMPasithea Therapeutics Corp.barrons.com - June 5 at 4:28 PMmarketbeat.com - June 5 at 8:57 AMFinancialnewsmedia.com: Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029finanznachrichten.de - June 1 at 11:34 AMPasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conferencefinance.yahoo.com - June 1 at 11:34 AMPasithea Therapeutics First Quarter 2023 Earnings: US$0.13 loss per share (vs US$0.068 loss in 1Q 2022)finance.yahoo.com - May 14 at 9:51 AMPasithea Therapeutics to Participate in EF Hutton Inaugural Global Conferencefinance.yahoo.com - May 3 at 10:41 AMPasithea Therapeutics files for $15M mixed shelf offeringseekingalpha.com - April 1 at 2:07 PMPasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meetingfinance.yahoo.com - March 2 at 3:30 PMPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)finance.yahoo.com - February 23 at 6:57 PMPasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Awardfinance.yahoo.com - February 16 at 8:03 AMKTTA Pasithea Therapeutics Corp.seekingalpha.com - January 25 at 7:41 PMPasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004finance.yahoo.com - January 18 at 10:28 AMPasithea Therapeutics Corp. (KTTA)finance.yahoo.com - January 16 at 8:04 PMMajority of Stockholders Support Pasithea Directors at Special Meetingfinance.yahoo.com - December 14 at 6:37 PMPasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conferencefinance.yahoo.com - December 6 at 5:27 PMPasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Timefinance.yahoo.com - November 28 at 8:17 PMInvestor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeuticsfinance.yahoo.com - November 22 at 8:26 PM Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Protect Yourself While There’s Still Time … (Ad)The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom. 4 simple steps to protect your privacy and money before it’s too late. KTTA Media Mentions By Week KTTA Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KTTA News Sentiment▼0.340.32▲Average Medical News Sentiment KTTA News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KTTA Articles This Week▼10▲KTTA Articles Average Week Get Pasithea Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KTTA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Can-Fite BioPharma News eFFECTOR Therapeutics News Pulmatrix News Chemomab Therapeutics News Lixte Biotechnology News Trevena News Clever Leaves News Tenax Therapeutics News ASLAN Pharmaceuticals News Universe Pharmaceuticals News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KTTA) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pasithea Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
